Skip to content
value.today

Viela Bio, Inc.

🇺🇸 Gaithersburg, Maryland, USABiotechnologyFounded 2017
Total raised
$357 M
2 rounds on record
Latest round
$75 M
Jun 2019
First round on record
Feb 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Viela Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$75 MNo. 2$50 to $250 million

Viela Bio, Inc.: Raise no. 2, Jun 2019

Investors in this round

9 investors had bought by the notice of Jun 26, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Viela Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$250,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Zhengbin (Bing) Yao · Executive Officer, Director
  • Andreas Wicki · Director
  • Edward Hu · Director
  • Pascal Soriot · Director
  • Tyrell Rivers · Director
  • Wenkai Xiang · Director
  • Xiaomeng Tong · Director
  • Yanling Cao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Solebury Capital LLC (CRD 14399) · New York, New YorkSold in all US states

Signed by Zhengbin (Bing) Yao, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 26, 2019. Read the notice at the SEC.

equitySEC
Feb 2018$282 MNo. 1$250 million to $1 billion

Viela Bio, Inc.: Raise no. 1, Feb 2018

Investors in this round

7 investors had bought by the notice of Mar 15, 2018: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Viela Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$282 M of $312 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew (Bing) Pietras · Executive Officer · Treasurer
  • Zhengbin (Bing) Yao · Executive Officer, Director · Chief Executive Officer and Secretary
  • Bahija (Bing) Jallal · Director
  • Ting (Bing) Jia · Director
  • Tyrell Rivers · Director
  • Wenkai (Bing) Xiang · Director
  • Xiaomeng (Bing) Tong · Director
  • Yanling (Bing) Cao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhengbin (Bing) Yao, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 15, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Viela Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2019

That is all the official record says: Viela Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Viela Bio, Inc.
InvestorKindAmountRoundRoleSource
Astrazeneca PLCCompanynot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
AstraZeneca UK LTDCompanynot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Boundless Meadow LtdCompanynot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Boyu Capital Fund III, L.P.Fund or asset managernot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Boyu Capital General Partner III, L.P.Fund or asset managernot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Boyu Capital General Partner III, Ltd.Fund or asset managernot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Boyu Capital Group Holdings Ltd.Fund or asset managernot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
XYXY Holdings Ltd.Companynot statednot statedHeld Series A-2 and A-3 preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Viela Bio, Inc.
NameRoleNamed in
Zhengbin (Bing) YaoExecutive officerJun 2019
Matthew (Bing) PietrasTreasurerMar 2018
Andreas WickiDirectorJun 2019
Edward HuDirectorJun 2019
Pascal SoriotDirectorJun 2019
Tyrell RiversDirectorJun 2019
Wenkai XiangDirectorJun 2019
Xiaomeng TongDirectorJun 2019
Yanling CaoDirectorJun 2019
Zhengbin (Bing) YaoDirectorJun 2019
Bahija (Bing) JallalDirectorMar 2018
Ting (Bing) JiaDirectorMar 2018
Wenkai (Bing) XiangDirectorMar 2018
Xiaomeng (Bing) TongDirectorMar 2018
Yanling (Bing) CaoDirectorMar 2018